Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Straus, D, Collins, G, Walewski, J, Zinzani, PL, Grigg, A, Sureda, A, Illes, A, Kim, TM, Alekseev, S, Specht, L, Buccheri, V, Younes, A, Connors, J, Forero-Torres, A, Fenton, K, Gautam, A, Purevjal, I, Liu, R & Gallamini, A 2020, 'Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy', Leukemia and Lymphoma, bind 61, nr. 12, s. 2931-2938. https://doi.org/10.1080/10428194.2020.1791846

APA

Straus, D., Collins, G., Walewski, J., Zinzani, P. L., Grigg, A., Sureda, A., Illes, A., Kim, T. M., Alekseev, S., Specht, L., Buccheri, V., Younes, A., Connors, J., Forero-Torres, A., Fenton, K., Gautam, A., Purevjal, I., Liu, R., & Gallamini, A. (2020). Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leukemia and Lymphoma, 61(12), 2931-2938. https://doi.org/10.1080/10428194.2020.1791846

CBE

Straus D, Collins G, Walewski J, Zinzani PL, Grigg A, Sureda A, Illes A, Kim TM, Alekseev S, Specht L, Buccheri V, Younes A, Connors J, Forero-Torres A, Fenton K, Gautam A, Purevjal I, Liu R, Gallamini A. 2020. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leukemia and Lymphoma. 61(12):2931-2938. https://doi.org/10.1080/10428194.2020.1791846

MLA

Vancouver

Author

Straus, David ; Collins, Graham ; Walewski, Jan ; Zinzani, Pier Luigi ; Grigg, Andrew ; Sureda, Anna ; Illes, Arpad ; Kim, Tae Min ; Alekseev, Sergey ; Specht, Lena ; Buccheri, Valeria ; Younes, Anas ; Connors, Joseph ; Forero-Torres, Andres ; Fenton, Keenan ; Gautam, Ashish ; Purevjal, Indra ; Liu, Rachael ; Gallamini, Andrea. / Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. I: Leukemia and Lymphoma. 2020 ; Bind 61, Nr. 12. s. 2931-2938.

Bibtex

@article{161d624f55324b9d89f77e2ea00e09fa,
title = "Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy",
abstract = "We investigate the impact of granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (G-PP, N = 83) versus no G-PP (N = 579) on safety and efficacy of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) in the ECHELON-1 study of previously untreated stage III/IV classical Hodgkin lymphoma. G-PP was associated with lower incidence of ≥ grade 3 neutropenia (29% versus 70%) and febrile neutropenia (11% versus 21%). Fewer dose delays (35% versus 49%), reductions (20% versus 26%), and hospitalizations (29% versus 38%) were observed. Seven neutropenia-associated deaths occurred in the A + AVD arm; none received G-PP. A + AVD with G-PP was associated with decreased risk of a modified progression-free survival event by 26% compared with A + AVD alone (95% CI: 0.40-1.37). G-PP reduced the rate and severity of adverse events, including febrile neutropenia, reduced treatment delays, dose reductions, and discontinuations, and may thus improve efficacy outcomes. These data support G-PP for all patients treated with A + AVD.",
keywords = "Hodgkin lymphoma, brentuximab vedotin, frontline therapy, growth factor, primary prophylaxis",
author = "David Straus and Graham Collins and Jan Walewski and Zinzani, {Pier Luigi} and Andrew Grigg and Anna Sureda and Arpad Illes and Kim, {Tae Min} and Sergey Alekseev and Lena Specht and Valeria Buccheri and Anas Younes and Joseph Connors and Andres Forero-Torres and Keenan Fenton and Ashish Gautam and Indra Purevjal and Rachael Liu and Andrea Gallamini",
year = "2020",
month = dec,
doi = "10.1080/10428194.2020.1791846",
language = "English",
volume = "61",
pages = "2931--2938",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

RIS

TY - JOUR

T1 - Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

AU - Straus, David

AU - Collins, Graham

AU - Walewski, Jan

AU - Zinzani, Pier Luigi

AU - Grigg, Andrew

AU - Sureda, Anna

AU - Illes, Arpad

AU - Kim, Tae Min

AU - Alekseev, Sergey

AU - Specht, Lena

AU - Buccheri, Valeria

AU - Younes, Anas

AU - Connors, Joseph

AU - Forero-Torres, Andres

AU - Fenton, Keenan

AU - Gautam, Ashish

AU - Purevjal, Indra

AU - Liu, Rachael

AU - Gallamini, Andrea

PY - 2020/12

Y1 - 2020/12

N2 - We investigate the impact of granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (G-PP, N = 83) versus no G-PP (N = 579) on safety and efficacy of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) in the ECHELON-1 study of previously untreated stage III/IV classical Hodgkin lymphoma. G-PP was associated with lower incidence of ≥ grade 3 neutropenia (29% versus 70%) and febrile neutropenia (11% versus 21%). Fewer dose delays (35% versus 49%), reductions (20% versus 26%), and hospitalizations (29% versus 38%) were observed. Seven neutropenia-associated deaths occurred in the A + AVD arm; none received G-PP. A + AVD with G-PP was associated with decreased risk of a modified progression-free survival event by 26% compared with A + AVD alone (95% CI: 0.40-1.37). G-PP reduced the rate and severity of adverse events, including febrile neutropenia, reduced treatment delays, dose reductions, and discontinuations, and may thus improve efficacy outcomes. These data support G-PP for all patients treated with A + AVD.

AB - We investigate the impact of granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (G-PP, N = 83) versus no G-PP (N = 579) on safety and efficacy of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) in the ECHELON-1 study of previously untreated stage III/IV classical Hodgkin lymphoma. G-PP was associated with lower incidence of ≥ grade 3 neutropenia (29% versus 70%) and febrile neutropenia (11% versus 21%). Fewer dose delays (35% versus 49%), reductions (20% versus 26%), and hospitalizations (29% versus 38%) were observed. Seven neutropenia-associated deaths occurred in the A + AVD arm; none received G-PP. A + AVD with G-PP was associated with decreased risk of a modified progression-free survival event by 26% compared with A + AVD alone (95% CI: 0.40-1.37). G-PP reduced the rate and severity of adverse events, including febrile neutropenia, reduced treatment delays, dose reductions, and discontinuations, and may thus improve efficacy outcomes. These data support G-PP for all patients treated with A + AVD.

KW - Hodgkin lymphoma

KW - brentuximab vedotin

KW - frontline therapy

KW - growth factor

KW - primary prophylaxis

U2 - 10.1080/10428194.2020.1791846

DO - 10.1080/10428194.2020.1791846

M3 - Journal article

C2 - 32842815

VL - 61

SP - 2931

EP - 2938

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -

ID: 61755772